Farmas USA

Deduzco que andas de Viagra entonces hoy, que te ahorras hasta la foto de las animadoras.

Buenos días! ¿Os acodáis de ELAN?

"Elan says Amarin deal 'still an opportunity we are considering'"

Pues mira por donde, acaba ser ella objeto de adquisición:

El fabricante estadounidense de genéricos Perrigo adquiere la irlandesa Elan por 6.473 millones

El fabricante estadounidense de medicamentos genéricos Perrigo ha llegado a un acuerdo definitivo para adquirir la empresa de biotecnología irlandesa Elan por 8.600 millones de dólares (6.373 millones de euros), según informó la empresa en un comunicado.

Perrigo llevará a cabo esta operación mediante un nuevo holding constituido en Irlanda, denominado New Perrigo, y supone el fin del proceso formal de venta iniciado por Elan, durante el cual la empresa irlandesa ha rechazado otras ofertas.

El valor de la compra, que se abonará en efectivo y acciones, se ha fijado en función del precio de cierre de los títulos de Elan a fecha de 26 de julio. En concreto, los accionistas de Elan recibirán 6,25 dólares en efectivo y 0,07636 acciones de New Perrigo por cada título de Elan que posean, lo que supone valorarlos en 16,5 dólares.

Según el fabricante estadounidense, esta operación creará una compañía sanitaria global con un perfil de crecimiento líder en el sector y con el "tamaño y el alcance geográfico" para continuar creando un negocio "verdaderamente diferenciado".

El presidente y consejero delegado de Perrigo, Joseph C. Papa, afirmó que con esta adquisición la compañía establece "una plataforma diversificada para una mayor expansión internacional", y defendió que la operación es "atractiva" para los accionistas de Elan y tiene plenamente en cuenta el valor de sus activos.

Esta en la que ando metido tras la última dilución, anuncia para el 8 de agosto una presentación de la situación empresarial así como los resultados financieros del 2Q

http://yhoo.it/138BKi6

MACK

Synta Announces ENCHANT-1 Breast Cancer Results Support Transition to Second Stage of Trial
– Trial evaluating ganetespib monotherapy in HER2-positive and triple-negative breast cancer meets preplanned expansion criteria –

– Complete clinical response and surgical restaging in TNBC patient following treatment with single-agent ganetespib --

LEXINGTON, Mass.--(BUSINESS WIRE)--Jul. 29, 2013-- Synta Pharmaceuticals Corp. (NASDAQ: SNTA) announced today that preliminary results from the ENCHANT-1 clinical trial, which evaluates ganetespib monotherapy in patients with newly diagnosed locally advanced or metastatic HER2 positive or triple-negative breast cancer (TNBC), achieved the prespecified criteria for advancing to the second stage of the trial.

Of the initial five HER2-positive patients enrolled in the study, two achieved objective tumor response and two achieved stable disease (SD) within the three cycles of treatment on study (12 weeks). Of the initial ten TNBC patients enrolled and evaluable for response, two achieved objective tumor response and three achieved SD following treatment with ganetespib monotherapy.

ENCHANT-1 is a ‘window-of-opportunity’ study designed to evaluate the clinical activity of single-agent ganetespib over a 12-week period preceding standard first line treatment. The protocol specifies advancing to the second stage of enrollment in each cohort if there was at least one objective tumor response out of the initial fifteen evaluable patients specified for Stage 1. This criterion was achieved in both cohorts, and therefore both cohorts will continue to enroll patients up to a total of 33 evaluable patients per cohort.

Metabolic response was also assessed in the study, by comparing baseline and week 3 PET scans. Of the five HER2-positive patients, four achieved metabolic responses. Of the 13 TNBC patients with post-baseline PET scans, six achieved metabolic response.

“Ganetespib appears to be what many of us in the Hsp90 field have been seeking for many years: a well tolerated, highly potent Hsp90 inhibitor that is clinically active in tough-to-treat cancers,” said Dr. Neil Spector, Co-Director of Developmental Therapeutics Program, Duke University and an investigator on the trial. “Given the known role of Hsp90 in fueling breast cancer growth and metastasis, and the single-agent activity seen with ganetespib, I believe this compound has potential to be an important new therapy for women with breast cancer.”

Among the patients enrolled in the study is a 68 year old woman diagnosed with inoperable TNBC, including extensive disease that had spread to her lymph nodes. The week 3 PET scan showed metabolic response in all lesions and the week 12 physical exam showed no evidence of tumor. Treatment was adjudicated a complete clinical response, and her disease was restaged from inoperable to operable. Earlier this month, she successfully completed a mastectomy with curative intent.

“It is quite remarkable to see such a strong clinical response in this devastating disease, particularly with a single-agent regimen this well tolerated,” said Dr. Tamas Hickish, Professor at the Royal Bournemouth Hospital, Dorset, UK, the treating physician and an investigator on the study. “This outcome strongly supports the further investigation of ganetespib either as a single-agent or in combination with standard of care treatments used in this setting.”

Consistent with prior experience in over 700 patients treated with ganetespib to date, the most common adverse event seen with ganetespib in the ENCHANT-1 trial was mild to moderate, transient diarrhea, which was generally manageable with standard medication.

“These encouraging findings confirm prior signals of clinical activity seen with ganetespib in breast cancer,” said Dr. Iman El-Hariry, Vice President of Clinical Research at Synta. “The favorable safety profile, clear single-agent clinical activity, and strong rationale for combination therapy suggest ganetespib may have broad potential utility in breast cancer. Taxanes in particular are widely used in breast cancer. The positive results for the combination of ganetespib with docetaxel in lung cancer provide strong rationale for exploring the taxane combination regimen in breast cancer as well.”

The expansion of the ENCHANT-1 trial will also allow for evaluation of the combination of weekly paclitaxel and ganetespib. Separately, an investigator-sponsored study evaluating the combination of ganetespib, paclitaxel, and trastuzumab in HER2-positive patients is initiating at MSKCC and NYU.

Results from ENCHANT-1 are expected to be presented at a medical meeting later this year.

SNTA

Entré en 6,40 a primeros de marzo y no me sali a principios de julio de milagro. Ahora espero que rompa los 7.72 y si lo hace con volumen me quedo. Hoy de todas maneras puede hacer un poquito de pullback

ohhh, se me olvidó adjuntarla.
Mujer, seria la leche ir a currar hoy puesto de viagra.
Cuando he entrado al banco pareceria que voy a atracarlo , con la pistola en el bolsillo del pantalón!!!
habria sido la risa; me pongo un pañuelo tapando la cara, miro a la subdirectora de la oficina que he visitado (que está bastante buena)y le grito , Esto es un atraco! y lo que no paras de mirar y mi entrepierna es una pistola!!!
jajaja

Synta Pharmaceuticals Corp. Pre-Market Trading
$5.60 +0.54 ↑10.67% 41.195 shares

Read more: http://www.nasdaq.com/symbol/snta/premarket#ixzz2aR9Ueyxg

Bien, bien, bien!!!!!!!!!!!!!!!!!!!!!

Vaya GAP, ehhhh